医学
西妥昔单抗
结直肠癌
福尔菲里
贝伐单抗
伊立替康
无进展生存期
肿瘤科
危险系数
癌症
克拉斯
内科学
帕尼单抗
胃肠病学
总体生存率
化疗
置信区间
作者
Sebastian Stintzing,Susanne Klein‐Scory,Ludwig Fischer von Weikersthal,Martin Fuchs,Florian Kaiser,Kathrin Heinrich,Dominik Paul Modest,Ralf‐Dieter Hofheinz,Thomas Decker,Armin Gerger,Stefan Angermeier,Holger Rumpold,Andreas Dickhut,Leopold Öhler,Birgit Gruenberger,Dora Niedersuess‐Beke,Matthias Sandmann,Thomas Winder,Jörg Trojan,Gerald W. Prager
摘要
LB allows the detection of RAS and BRAF mutations in patients deemed RASwt on the basis of tissue analyses. These patients show outcome characteristics expected for RAS- and BRAF-mutant patients in tissue. The study thus confirms the high clinical relevance of LB performed at baseline before the start of therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI